Clinical Trial Update: Bioequivalence Study of Capsule and Tablet Formulations of TA-8995 [Phase 1]

View source ↗

Summary

Completed Phase 1 bioequivalence study comparing capsule and tablet formulations of TA-8995 for dyslipidemia, sponsored by Xention Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• TA-8995

Snippet

Sponsor: Xention Ltd | Conditions: Dyslipidaemia | Phase 1 | Status: COMPLETED